🌟 We are proud to present 7 accepted scientific abstracts at #EUSOBI 2026, showcasing groundbreaking research in AI-driven screening, triage, risk stratification, and density assessment. Join scientific presentation sessions and explore our study findings, connect with our authors, and see how clinically proven AI is transforming daily practice! Stop by Lunit Booth #R05 to discuss our research, experience live demos, and 1:1 expert discussions with our clinical specialists. 👋 Book your 1:1 meeting here: microsite.lunit.io/eusobi#me… #EUSOBI2026 #BreastImaging #RadiologAI #ClinicalEvidence #Lunit #LunitINSIGHT

Heading to EUSOBI 2026? Don’t just hear about AI in breast screening - see how it performs in real clinical practice. We are excited to invite you to our hands-on workshops co-hosted with @FujifilmEMEA and welcome you to Room 0.8 (MECC, Ground floor) At the workshop, you will gain practical experience analyzing complex breast cases with Lunit AI, guided by experienced clinical experts in both screening and symptomatic workflows! 💡 Learn more about the workshop: microsite.lunit.io/eusobi Looking for a closer look or a tailored consultation after the workshop? Stop by our booth (hashtag#R05) to meet our Europe team and explore: • Live 1-on-1 workflow demos • Discussion on integrating advanced AI into your daily practice 👋 Book your 1:1 meeting here: microsite.lunit.io/eusobi We look forward to seeing you in Maastricht! @EUSOBIyc #BreastScreening #RadiologyAI #Lunit #EUSOBI

👏 That’s a wrap on an incredible AOCR-SGCR 2026 in Singapore! 👏 What an unforgettable few days connecting with the radiology community at SGCR-WIRES. Throughout the event, our team had the privilege of meeting so many passionate radiologists and clinical professionals. It was a fantastic opportunity to discuss real-world practice and demonstrate how our AI solutions integrate into reading workflows to support earlier, more confident detection. We also loved seeing so many visitors enjoy our interactive in-booth events, especially the lively energy around our Lunit BINGO🎯 game during lunch hours! A heartfelt thank you to everyone who dropped by and made our presence at AOCR-SGCR so meaningful. A big shoutout as well to our ASIA team for their dedication and incredible energy! Jin Park, SAEROM HAM, Karen Gill, Rohan Lal, Adrian Falconer Missed us at the booth or interested in exploring Lunit’s AI solutions for your institution? 👋 Connect with our team today or learn more here: lunit.io/en/contact-us/?utm_… See you at our next stop in Europe (EUSOBI & JFR 2026)! #MedicalAI #CancerSreening #HealthcareAI #Lunit

👋Heading to AOCR-SGCR 2026 in Singapore? Come say hello at Booth D2! We’re excited to be joining radiology professionals from across the region at one of Asia’s leading imaging congresses. Stop by to meet the Lunit Asia team and see how our AI solutions, including LunitINSIGHT® CXR and LunitINSIGHT® Breast Suite, are supporting radiologists in everyday clinical practice. We’ve also got a few fun activities planned at the booth: 📸 Polaroid Photo Zone Take home a wide Polaroid photo in a custom Lunit frame to remember the event. 🎯 Lunit BINGO! Spin the Wheel of Names, complete four words in a row, and win a surprise prize. Everyone who takes part receives a gift! Come meet our Asia team. We'd love to chat and show you what's new at Lunit. 📍 Lunit Booth D2, Singapore EXPO 📅 20–23 August 2026 🔗 Book a meeting here: microsite.lunit.io/sgcr-wire… #AOCRSGCRWIRES2026 #SGCRWIRES #Lunit #LunitINSIGHT #RadiologyAI #MedicalAI #radiology #radiologist #Singapore #BreastScreening #CancerScreening

Don't miss the #AI Advances in #Radiology Webinar tomorrow with David Gruen, MD, Nancy Walker and @RajeshBhayana_ . Register now at: registration.diagnosticimagi… @RadiologyACR @ARRS_Radiology @RSNA @Lunit_AI @CoronisHealth @imagingtoronto #RadRes

“More for Less” Isn’t a Theory. It’s Already happening in Breast Screening. 📰 A recent The Wall Street Journal article highlights a powerful shift in Sweden’s healthcare system: delivering more outcomes with fewer resources. At St. Göran’s Hospital in Stockholm, that shift is real—and measurable. Radiologist Karin Dembrower describes identifying cancers that “we cannot see with our eyes”…yet AI can. The result isn’t just better detection. It’s a fundamentally different operating model. Read more: wsj.com/world/europe/the-wor…

🎉 We're thrilled to share that Lunit INSIGHT® CXR4 is now approved by Health Canada! 🇨🇦 We're proud to bring our most advanced chest X-ray AI to care teams across Canada, with features designed to support radiologists at every step: ✅ Detects 11 abnormalities across dozens of diagnoses ✅ Normal Flagging powered by DualScan System ✅ Acute Bone Fracture Detection ✅ Expanded Current-Prior Comparison 👉 Learn more about Lunit INSIGHT CXR4: lunit.io/en/ai-radiology-sof… #Lunit #CXR #Radiology #ChestXray #Chestscreening #Healthcanada

The latest NCCN Breast Cancer Screening & Diagnosis Guidelines (v1.2026) includes a pivotal update: image‑based risk assessment is now recognized as a valid way to identify women at increased risk of invasive breast cancer. Image-based risk is a 5-year breast cancer risk assessment approach that can be derived from routine, negative, screening mammograms. By recognizing this as complementary to traditional clinical and hereditary risk models, the NCCN guidelines introduce a new pathway of visibility into an individual’s risk of breast cancer. With this update, clinicians have a new option to support patients identified as “increased risk” with: ✅ Tailored screening strategies ✅ Additional surveillance ✅ Ongoing risk reassessment ✅ Consideration of counseling for risk reduction strategies At Lunit, we see this as an important step toward more accessible, image-driven breast cancer risk assessment. It also underscores the importance of innovations like Lunit INSIGHT Image-Based Risk – a solution designed to estimate a woman’s 5-year breast cancer risk using routine mammographic images and age. The model received FDA Breakthrough Device Designation in 2025 and is currently under 510(k) review. #Lunit #breastcancer #riskassessment #breastscreening #mammography

🩵 NCoBC 2026 wrapped up this weekend, and we're still thinking about the conversations we had there. There's something about a room full of people who have dedicated their careers to breast cancer care that puts things in perspective. This year felt especially meaningful with the conference celebrating its 35th anniversary, a testament to how far the field has come and how much further this community is committed to taking it. Brian Drohan, PhD, Medical Science Liaison at Lunit, opened Monday morning with a session on risk assessment in contemporary practice. He walked through where science is today and where it's headed. It was a great way to close out the weekend. To everyone who stopped by and connected with us, thank you! The conversations we have at events like this remind us why this work matters. 🙌 👉Couldn't make it to NCoBC? We'd love to connect and share more about how our AI solutions are supporting breast centers: lunit.io/en/contact-us/ #NCoBC #ncobc2026 #breastcancer #AI #Lunit #riskassessment #EarlyDetection #Mammography #breastscreening

Screening is more than early detection. It improves survival in stage IV breast cancer. For years, mammography has been discussed mainly as a way to detect cancer early. New research in the Journal of the National Cancer Institute shows its impact reaches much further than that. A study of more than 817,000 women in Denmark found a dramatic difference in five‑year net survival for women diagnosed with Stage IV breast cancer: → Screen-detected: 74.7% → Never-screened: 32.4% This gap is not explained by lead‑time bias. Screen‑detected Stage IV cancers were more likely to be oligometastatic and far more likely to be treated surgically. 67% of screen‑detected cases were candidates for surgery, compared with 23% percent in women who were never screened. Screening doesn’t just find cancer earlier. It changes the clinical trajectory of advanced disease and expands what is treatable, even at Stage IV. As pressure on radiologists and technologists continues to increase, AI plays a growing role in supporting accuracy and consistency. These are the foundations that make life‑saving interventions possible. 🔗 Read the full study: pubmed.ncbi.nlm.nih.gov/4170… #breastcancer #cancer #mammography #breastscreening #Lunit

📷 What an inspiring week in Vienna! It was fantastic to connect with so many clinicians, researchers, and partners from across Europe during #ECR. Thank you for visiting us! One of the highlights of this year’s ECR was our hands-on workshops. Attendees reviewed clinical cases with AI outputs and experienced how AI can support both screening and symptomatic breast imaging in practice. We were also honored to host a symposium and share valuable perspectives from across Europe on the real-world successes, ongoing challenges, and future directions of AI adoption in screening mammography. We are very grateful to our partners at #Fujifilm for co-organizing the workshops and symposium with us! And of course, a big thank you to the Lunit team on the ground in Vienna. It was great to share such a busy and rewarding week together. 👋 We look forward to continuing the conversation and advancing AI together. See you again soon! 👀 Missed our booth at ECR? Don’t worry, we can still connect. If you’d like to learn more about our AI solutions or schedule a meeting with our team, 🔗 contact us here: lunit.io/en/contact-us/ #Lunit #ECR #medicalAI #cancersreening #radiology

.@Harrison_ai Continues to Grow Open #Platform Ecosystem, Welcomes Four New #AI Partners -@AIRAmed_GmbH @KoiosMed @Lunit_AI and @nanox_vision AI | #radiology businesswire.com/news/home/2…

New #Mammography Study Suggests #AI May Predict #BreastCancer Detection in Subsequent Screening diagnosticimaging.com/view/n… @RadiologyACR @ARRS_Radiology @RSNA @BreastImaging @UABRadiology @WCMRadiology @BrighamRad @OSURadiology @PennRadiology @Lunit_AI #radiology #RadRes #ECR2026

In May last year, we established Lunit Japan Inc. to strengthen our on-the-ground presence and work even more closely with #FUJIFILM through a complementary go-to-market strategy designed to expand access and drive growth in Japan. With rising imaging demand, workforce shortages, and a high reliance on general practitioners for image interpretation, we see clear opportunities for AI to help enhance reading performance and clinical workflows. In close collaboration with FUJIFILM, the latest version of FUJIFILM’s CXR-AID, incorporating Lunit’s AI technology, has now been launched in Japan for chest screening. Since its initial release in 2021, CXR-AID has been adopted by more than 4,000 medical institutions in Japan. 🔗Read more: fujifilm.com/fms/ja/news/371 #Lunit #INSIGHTCXR #CXR #chestscreening #medicalAI #healthcareAI #Japan

We’re excited to be back in Vienna soon for #ECR2026 🇦🇹 and we’d love to meet you in person. At Lunit, we work closely with clinicians to understand what actually helps in day-to-day practice. At this year’s ECR, we’ll be sharing how our latest AI solutions for chest and breast imaging are already being used in real clinical workflows across Europe. Visit us at booth AI-10 to meet the team, see live demos, and have an open conversation about how AI can support confident image interpretation in your own environment. 👉 Book your meeting with us at ECR 2026: microsite.lunit.io/meet-luni… Experience AI built for real clinical workflows at ECR 2026! @myESR #Lunit #ECR #chestscreening #breastscreening #radiology #medicalAI

Italy introduces new AI screening guidelines: Redefining double-reading with AI In a major policy shift, #Italy has become the first country in Europe to recommend using AI, not just to assist with mammogram interpretation, but to intelligently triage which exams require #double_reading. Under the new national guidelines, AI is used upfront to classify mammograms by risk level: only higher-risk cases are reviewed by two radiologists, while lower-risk exams may be read by a single reader. Read the full article: en.ilsole24ore.com/art/breas… Our breast AI has already supported double-reading screening programs to manage workload and detect cancers earlier in Europe. 👉Discover how our AI is applied in clinical practice: lunit.io/en/media-hub/real-w… #Lunit #breastcancer #breastscreening #mammography #radiology

BreastScreen NSW expands AI-supported mammography reading to all first-time screeners. Following a successful rollout over the past 12 months, BreastScreen NSW has expanded machine reading technology to include mammography images from all women attending screening for the first time. 👉 Read the full article here: cancer.nsw.gov.au/what-we-do… 📌 The impact is clear: fewer unnecessary recalls, reduced anxiety for women, with no compromise in cancer detection. Every exam continues to be read by a radiologist, with AI providing additional analysis to support confidence and efficiency in real-world clinical workflows. Through its collaboration with Lunit, BreastScreen NSW became the world’s first nationally governed cancer screening program to integrate AI. By deploying Lunit INSIGHT MMG as a second reader, the program enhances early detection, eases radiologist workload, and helps future-proof screening services amid global workforce shortages. #Lunit #LunitINSIGHT #BreastScreening #Mammography #BreastCacner #BSNSW #Australia

🩺 Breast density shouldn’t dictate how confident a screening read can be — but today, it still has a major impact. A recent article in The Imaging Wire highlights how significantly dense breast tissue reduces mammography accuracy, even when using digital breast tomosynthesis (DBT). This growing body of evidence highlights why decision support in DBT matters more than ever — especially as density notification requirements and supplemental screening conversations expand. Lunit INSIGHT DBT is designed to support more consistent interpretation in dense breasts by providing: • AI-assisted analysis for DBT, highlighting suspicious findings across complex, multi-slice exams • Consistent performance across breast types, including both fatty and dense tissue • AI-guided navigation and workflow support that simplifies slice selection and DBT review As screening programs work to deliver confidence and consistency across diverse patient populations, tools that help radiologists navigate density-related limitations may play an increasingly important role. 👉 Read the article: Breast Density’s Impact on Mammography - The Imaging Wire 👉 Learn more about Lunit INSIGHT DBT: AI-Assisted Mammography for 3D Detection | Lunit #Lunit #BreastImaging #DenseBreasts #DBT #AIinRadiology #Mammography #RadiologyAI

We recently announced the 510(k) submission of Lunit INSIGHT Risk, our mammography-based model for predicting a woman’s five-year breast cancer risk without patient questionnaires.​ ​ But where did this breakthrough begin, and what could it mean for the future of screening? ​ ​ Dr. Graham Colditz, who co-developed the image-based risk model (formerly known as Prognosia Breast) with Prof. Shu (Joy) Jiang at Washington University, St. Louis, dives into these questions in a recent article. ​ ​ In the article, Dr. Colditz shares his vision for personalized screening, the real-world challenges they aimed to solve, and how AI-powered risk modeling could help us move beyond the limitations of traditional tools, enabling more equitable, scalable, and proactive care.​ ​ 📌 Read the full article and explore the future of precision prevention: volparahealth.com/news/the-f… ​ #Lunit #LunitINSIGHTRisk #breastcancer #riskprediction #medicalAI #radiology #FDA